Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential

References

• Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc. 2005;103:537–567.
   PubMedGoogle Scholar
• Gass JD. Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol. 1995;119(6): 752–759.
   PubMed Web of Science ®Google Scholar
• Sonmez K, Capone A Jr, Trese MT, Williams GA. Vitreomacular traction syndrome: impact of anatomical configuration on anatomical and visual outcomes. Retina. 2008;28(9):1207–1214.
   PubMed Web of Science ®Google Scholar
• Margherio RR, Trese MT, Margherio AR, Cartright K. Surgical management of vitreomacular traction syndromes. Ophthalmology. 1989;96(9):1437–1445.
   PubMed Web of Science ®Google Scholar
• Melberg NS, Williams DS, Balles MW, et al. Vitrectomy for vitreomacular traction syndrome with macular detachment. Retina. 1995;15(3): 192–197.
   PubMed Web of Science ®Google Scholar
• Yamada N, Kishi S. Tomographic features and surgical outcomes of vitreomacular traction syndrome. Am J Ophthalmol. 2005;139(1): 112–117.
   PubMed Web of Science ®Google Scholar
• Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99(5):753–759.
   PubMed Web of Science ®Google Scholar
• Harbour JW, Smiddy WE, Flynn HW Jr, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol. 1996;121(4):405–413.
   PubMed Web of Science ®Google Scholar
• John VJ, Flynn HW Jr, Smiddy WE, et al. Clinical course of vitreomacular adhesion managed by initial observation. Retina. 2013. Epub August 7, 2013.
   PubMed Web of Science ®Google Scholar
• Hermel M, Dailey W, Hartzer MK. Efficacy of plasmin, microplasmin, and streptokinase-plasmin complex for the in vitro degradation of fibronectin and laminin – implications for vitreoretinal surgery. Curr Eye Res. 2010;35(5):419–424.
   PubMed Web of Science ®Google Scholar
• Chen W, Mo W, Sun K, Huang X, Zhang YL, Song HY. Microplasmin degrades fibronectin and laminin at vitreoretinal interface and outer retina during enzymatic vitrectomy. Curr Eye Res. 2009;34(12): 1057–1064.
   PubMed Web of Science ®Google Scholar
• Sazonova IY, Thomas BM, Gladysheva IP, Houng AK, Reed GL. Fibrinolysis is amplified by converting alpha-antiplasmin from a plasmin inhibitor to a substrate. J Thromb Haemost. 2007;5(10):2087–2094.
   PubMed Web of Science ®Google Scholar
• Elkareem GAM, Willekens B, Vanhove M, Noppen B, Stassen JM, de Smet MD. Characterization of a stabilized form of microplasmin for the induction of posterior vitreous detachment. Curr Eye Res. 2010;35(10):909–915.
   PubMed Web of Science ®Google Scholar
• Chen W, Huang X, Ma XW, Mo W, Wang WJ, Song HY. Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator. Eye. 2008;22(2):300–307.
   PubMed Web of Science ®Google Scholar
• Harooni M, McMillan T, Refojo M. Efficacy and safety of enzymatic posterior vitreous detachment by intravitreal injection of hyaluronidase. Retina. 1998;18(1):16–22.
   PubMed Web of Science ®Google Scholar
• Nasrallah FP, Jalkh AE, Van Coppenolle F, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95(10):1335–1339.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol. 2001;132(3):369–377.
   PubMed Web of Science ®Google Scholar
• Krebs I, Brannath W, Glittenberg C, et al. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144(5):741–746.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lee CS, Koh HJ. Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study. Am J Ophthalmol. 2009;147(4):621–626. e1.
   PubMed Web of Science ®Google Scholar
• Simpson A, Petrarca R, Jackson TL. Vitreomacular adhesion and neovascular age-related macular degeneration. Surv Opthalmol. 2012;57(6):498–509.
   PubMed Web of Science ®Google Scholar
• de Smet A, Gandorfer P, Stalmans P, et al. Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial Ophthalmology. 2009;116(7): 1349–1355.
   PubMed Web of Science ®Google Scholar
• Stalmans P, Delaey C, de Smet MD, et al. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial). Retina. 2010;30(7):1122–1127.
   PubMed Web of Science ®Google Scholar
• Benz MS, Packo KH, Gonzalez V, et al. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology. 2010;117(4): 791–797.
   PubMed Web of Science ®Google Scholar
• Stalmans P, Benz MS, Gandorfer A, et al; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367(7):606–615.
   PubMed Web of Science ®Google Scholar
• Garretson BR, Pollack JS, Ruby AJ, et al. Vitrectomy for asymptomatic lamellar macular hole. Ophthalmology. 2008;115(5):884–886.
   PubMed Web of Science ®Google Scholar
• Jost BF, Hutton WL, Fuller DG, et al. Vitrectomy in eyes at risk for macular hole formation. Ophthalmology. 1990;97(7):843–847.
   PubMed Web of Science ®Google Scholar
• Smiddy WE, Michels RG, Glaser BM, de Bustros SN. Vitrectomy for impending idiopathic macular hole. Am J Ophthalmol. 1988;105(4): 371–376.
   PubMed Web of Science ®Google Scholar
• de Bustros S. Vitrectomy for prevention of macular holes. Results of a randomized multicenter clinical trial. Vitrectomy for Prevention of Macular Hole Study Group. Ophthalmology. 1994;101(6):1055–1059.
   PubMed Web of Science ®Google Scholar
• Chan CK, Wessels IF, Friedrichsen EJ. Treatment of idiopathic macular holes by induced posterior vitreous detachment. Ophthalmology. 1995;102(5):757–767.
   PubMed Web of Science ®Google Scholar
• Rodrigues IA, Stangos AN, McHugh DA, Jackson TL. Intravitreal injection of expansile perfluoropropane (c(3)f(8)) for the treatment of vitreomacular traction. Am J Ophthalmol. 2013;155(2):270–276. e2.
   PubMed Web of Science ®Google Scholar
• Johnson MW. How should we release vitreomacular traction: surgically, pharmacologically, or pneumatically? Am J Ophthalmol. 2013;155(2):203–205. e1.
   PubMed Web of Science ®Google Scholar
• Jorge R, Costa RA, Cardillo JA, et al. Optical coherence tomography evaluation of idiopathic macular hole treatment by gas-assisted posterior vitreous detachment. Am J Ophthalmol. 2006;142(5):869–871.
   PubMed Web of Science ®Google Scholar
• Mori K, Saito S, Gehlbach PL, Yoneya S. Treatment of stage 2 macular hole by intravitreous injection of expansile gas and induction of posterior vitreous detachment. Ophthalmology. 2007;114(1):127–133.
   PubMed Web of Science ®Google Scholar
• Ochoa-Contreras D, Delsol-Coronado L, Buitrago ME, Velasco-Barona C, Quiroz-Mercado H. Induced posterior vitreous detachment by intravitreal sulfur hexafluoride (SF6) injection in patients with nonproliferative diabetic retinopathy. Acta Ophthalmol Scand. 2000;78(6): 687–688.
   PubMedGoogle Scholar
• Sebag J. Molecular biology of pharmacologic vitreolysis. Trans Am Ophthalmol Soc. 2005;103:473–494.
   PubMedGoogle Scholar
• Gandorfer A. Enzymatic vitreous disruption. Eye. 2008;22(10): 1273–1277.
   PubMed Web of Science ®Google Scholar
• Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol. 2011;5:1151–1165.
   PubMedGoogle Scholar
• Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci. 2004;45(2): 641–647.
   PubMed Web of Science ®Google Scholar
• de Smet MD, Valmaggia C, Zarranz-Ventura J, Willekens B. Microplasmin: ex vivo characterization of its activity in porcine vitreous. Invest Ophthalmol Vis Sci. 2009;50(2):814–819.
   PubMed Web of Science ®Google Scholar
• Shi GY, Wu HL. Isolation and characterization of microplasminogen; a low molecular weight form of plasminogen. J Biol Chem. 1988; 263(32):17071–17075.
   PubMed Web of Science ®Google Scholar
• Sakuma T, Tanaka M, Mizota A, et al. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes. Invest Ophthalmol Vis Sci. 2005;46(9):3295–3299.
   PubMed Web of Science ®Google Scholar
• Jetrea® (ocriplasmin). [package insert]. Iselin, NJ: ThromoGenics; 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/ 2012/125422s000 lbl.pdf. Accessed September 30, 2013.
   Google Scholar
• DeCroos FC, Toth CA, Folgar FA, et al. Characterization of vitreoretinal interface disorders using OCT in the interventional phase 3 trials of ocriplasmin. Invest Ophthalmol Vis Sci. 2012;53(10):6504–6511.
   PubMed Web of Science ®Google Scholar
• ThromboGenics. A multicenter study to compare multiple doses of intravitreal microplasmin versus sham injection for treatment of patients with diabetic macular edema (DME) (MIVI-II). Available from: http://clinicaltrials.gov/show/NCT00412451. NLM identifier: NCT00412451. Accessed September 30, 2013.
   Google Scholar
• Hikichi T, Fujio N, Akiba J, et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology. 1997;104(3): 473–478.
   PubMed Web of Science ®Google Scholar
• Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol. 2004;242(8):630–637.
   PubMed Web of Science ®Google Scholar
• Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20(2):126–133.
   PubMed Web of Science ®Google Scholar
• Gaucher D, Sebah C, Erginay A, et al. Optical coherence tomography features during the evolution of serous retinal detachment in patients with diabetic macular edema. Am J Ophthalmol. 2008;145(2): 289–296.
   PubMed Web of Science ®Google Scholar
• Gandorfer A. Role of vitreous in diabetic macular edema. Retina. 2012;32 Suppl 9:S211–S215.
   Google Scholar
• Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, Apte RS, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117(6):1087–1093.
   PubMed Web of Science ®Google Scholar
• Parolini B, Panuzzo G. Vitrectomy for nontractional diffuse diabetic macular edema: study design and preliminary results of the VIDE Study. Ophthalmology. 2006;113(S):193.
   Google Scholar
• Meyer CH. Current Treatment Approaches in Diabetic Macular Edema. Ophthalmologica. 2007;221(2):118–131.
   PubMed Web of Science ®Google Scholar
• Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci. 2012;53(9):5877–5880.
   PubMed Web of Science ®Google Scholar
• ThromboGenics. Safety and efficacy study of intravitreal ocriplasmin in subjects with amd with focal vitreomacular adhesion (MIVI-5). Available from: http://clinicaltrials.gov/show/NCT00913744. NLM identifier: NCT00913744. Accessed September 30, 2013.
   Google Scholar
• ThromboGenics. Safety and efficacy study of microplasmin in for non-surgical treatment of focal vitreomacular adhesion (MIVI-8). Available from: http://clinicaltrials.gov/show/NCT01055535. NLM identifier: NCT01055535. Accessed September 30, 2013.
   Google Scholar
• ThromboGenics. clinical trial of intravitreal microplasmin in infants and children scheduled for vitrectomy (MIC). Available from: http://clinicaltrials.gov/show/NCT00986362. NLM identifier: NCT00986362. Accessed September 30, 2013.
   Google Scholar
• Tsukahara Y, Honda S, Imai H, et al. Autologous plasmin assisted vitrectomy for stage 5 retinopathy of prematurity: a preliminary trial. Am J Ophthalmol. 2007;144(1):139–141.
   PubMed Web of Science ®Google Scholar
• Wu WC, Drenser KA, Lai M, et al. Plasmin enzyme-assisted vitrectomy for primary and reoperated eyes with stage 5 retinopathy of prematurity. Retina. 2008;28:S75–S80.
   PubMed Web of Science ®Google Scholar
• Wu WC, Drenser KA, Capone A, et al. Plasmin enzyme assisted vitreoretinal surgery in congenital X-linked retinoschisis: surgical techniques based on a new classification system. Retina. 2007;27(8):1079–1085.
   PubMed Web of Science ®Google Scholar
• Wu WC, Drenser KA, Trese MT, et al. Pediatric traumatic macular hole: results of autologous plasmin enzyme-assisted vitrectomy. Am J Ophthalmol. 2007;144(5):668–672.
   PubMed Web of Science ®Google Scholar
• Wong SC, Capone A Jr. Microplasmin (ocriplasmin) in pediatric vitreoretinal surgery: update and review. Retina. 2013:33(2):339–348.
   PubMed Web of Science ®Google Scholar
• ThromboGenics. The purpose of this study is to evaluate the pharmacokinetic properties of intravitreal ocriplasmin prior to planned primary pars plana vitrectomy (PPV) (MIVI-10). Available from: http://clinicaltrials.gov/show/NCT01159665. NLM identifier: NCT01159665. Accessed September 30, 2013.
   Google Scholar
• ThromboGenics. Follow-up study to assess visual function in subset of patients who have previously participated in the TG-MV-006 and TG-MV-007 ocriplasmin studies. Available from: http://clinicaltrials.gov/show/NCT01287988. NLM identifier: NCT01287988. Accessed September 30, 2013.
   Google Scholar
• ThromboGenics. Ocriplasmin for treatment for symptomatic vitreomacular adhesion/(VMT) including macular hole (OASIS). Available from: http://clinicaltrials.gov/show/NCT01429441. NLM identifier: NCT01429441. Accessed September 30, 2013.
   Google Scholar
• University of California, Los Angeles; ThromboGenics. Study of intravitreal microplasmin in relieving vitreo-macular adhesion in neovascular age-related macular degeneration (AMD). Available from: http://clinicaltrials.gov/show/NCT00996684. NLM identifier: NCT00996684. Accessed September 30, 2013.
   Google Scholar
• National Institutes of Health Clinical Center (CC); National Eye Institute (NEI). Microplasmin intravitreal administration in participants with uveitic macular edema (MIME). Available from: http://clinicaltrials.gov/show/NCT01194674. NLM identifier: NCT01194674. Accessed September 30, 2013.
   Google Scholar
• Goldenberg DT, Giblin FJ, Cheng M, et al. Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes. Retina. 2011;31(2):393–400.
   PubMed Web of Science ®Google Scholar
• Sebag J, Ansari RR, Suh KI. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients. Graefes Arch Clin Exp Ophthalmol. 2007;245(4):576–580.
   PubMed Web of Science ®Google Scholar
• Quiram PA, Leverenz VR, Baker RM, Dang L, Giblin FJ, Trese MT. Microplasmin-induced posterior vitreous detachment affects vitreous oxygen levels. Retina. 2007;27(8):1090–1096.
   PubMed Web of Science ®Google Scholar